Dr Reddys unveils COVID-19 drug Remdesivir under brand name Redyx in India

"Dr Reddy's Redyx is available in the strength of 100 mg vial," dr Reddy's said.

Published On 2020-09-10 08:46 GMT   |   Update On 2020-09-10 08:46 GMT
Advertisement

Hyderabad: Joining the initiative to launch popular drug Remdesivir to treat COVID-19 patients, Hyderabad-based Dr Reddys Laboratories Ltd. recently unveiled the formulation under a brand name ''Redyx'' in India.

According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Advertisement

Remdesivir is approved by the Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.

"Dr Reddy''s Redyx is available in the strength of 100 mg vial," it said.

Commenting on the launch, Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said, "We will continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India."

Tags:    
Article Source : with agency inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News